This broad-spectrum anthelmintic is applied in clinical settings that involve managing established mixed parasitic infestations in dogs. It is commonly used to help with both significant nematode species (roundworms, hookworms, and whipworms) and common cestodes (tapeworms). The main therapeutic benefit supports the patient during difficult episodes by easing the overall parasitic burden, which may assist with managing the underlying infection and supports general well-being during symptomatic phases.

The treatment is relevant for managing symptom clusters that may become intense or disruptive due to an internal parasitic burden. This includes assisting with symptoms related to physical discomfort and impaired nutrient absorption. Its application is relevant when multiple worm types are present and a comprehensive approach to easing the parasitic burden is needed. Through its intended action, it may also assist with limiting the potential risk of environmental contamination, especially concerning species like Echinococcus.

---

Quick Fact: Supportive management for Gastrointestinal Distress Dolpac 10 is commonly used in conditions presenting with acute episodes of worm infection, is used for managing physical discomfort and compromised nutrient absorption symptoms associated with the parasite's presence.

Regulatory References

1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility Map: Who Can and Cannot Use Dolpac 10

Dolpac 10 is a veterinary medicine intended for use in the target species, dogs. Official regulatory documents define specific populations for whom the medicine is contraindicated, restricted, or not recommended.

---

Eligibility Scope

Category	Official Regulatory Status
Use is Contraindicated	Animals with known hypersensitivity to Praziquantel, Oxantel, Pyrantel, or any other component.
Use is Not Recommended	Pups younger than two months old or those weighing less than 1 kg. Pregnant bitches and lactating bitches.
Conditional Use Required	Debilitated or heavily infested animals.

---

Official Eligibility Statements

The medicine is contraindicated in animals with a history of hypersensitivity to any of its active or inactive ingredients. Use is explicitly not recommended for pups under two months of age or weighing less than one kilogram. Furthermore, Dolpac 10 is not recommended for pregnant and lactating bitches, as safety has not been established in these populations. In cases involving debilitated or heavily infested animals, use must only proceed following a benefit/risk assessment by a veterinarian.

Interactions with other medicines and products

The interaction profile for Dolpac 10 is officially defined by specific constraints regarding simultaneous use with certain categories of medicinal products. Regulatory documentation explicitly lists drugs and drug classes that must not be co-administered due to the potential for interactions.

Documented Interaction Restrictions

Official labeling mandates that Dolpac 10 should not be used simultaneously with the following substances or product categories:

• Levamisole: Co-administration with this anthelmintic agent is restricted.
• Piperazine: Simultaneous use with this anthelmintic agent is restricted.
• Choline Esterase Inhibitors: The concurrent use of Dolpac 10 with any medicine classified as a choline esterase inhibitor is prohibited.

Practical Implications of the Interaction Profile

The structure of the official interaction information focuses on clear, necessary exclusion rules for co-administration. These restrictions are stated in governmental regulatory documents to prevent combinations with agents that may result in adverse effects. The primary constraint governing the use of this product is the requirement to avoid simultaneous use with the specifically identified anthelmintics and the entire class of choline esterase inhibitors, establishing a foundational guideline for safe use alongside other medicinal products.

How Dolpac 10 Works

The mechanism of Dolpac 10 relies on two distinct pharmacodynamic strategies targeting different parasite phyla.

Disruption of Tapeworm Structure via Calcium Flux

This domain covers the action of Praziquantel, a membrane permeability modulator, which rapidly increases the influx of calcium ions ( Ca^2+) across the tapeworm's outer membrane. This uncontrolled electrochemical change causes immediate, severe muscle spasm and structural damage to the parasite's tegument. The resulting physiological failure prevents the worm from maintaining adherence to the intestinal wall, facilitating its clearance by the host's normal digestive action and peristalsis.

---

️ Nematode Paralysis through Nicotinic Receptor Agonism

This domain details how Pyrantel and Oxantel act as neuromuscular agonists, binding to specific nicotinic acetylcholine receptors ( nAChR) on the muscle cells of roundworms. This persistent binding causes sustained muscle depolarization and a state of spastic paralysis. The paralysis prevents the worm from executing coordinated movement or anchoring itself, resulting in its mechanical displacement and expulsion via the host's peristalsis. Oxantel acts on specific nAChR subtypes to include coverage against certain nematodes less affected by Pyrantel, resulting in a wider combined mechanistic action against mixed infestations.

The administration of Dolpac 10 is based on a precise, weight-dependent protocol. The medicine is intended for oral administration in a single course of treatment, establishing a short-term usage pattern.

---

Administration Scope: Guidelines

Administration Scope	Description
Route of administration	Oral route (administer by mouth).
Dosing schedule	One tablet per 10 kg of body weight. The dose rate is 20 mg Oxantel, 5 mg Pyrantel, and 5 mg Praziquantel per kg bodyweight.
Timing in relation to meals	Fasting is preferred prior to treatment. Food may be given one hour or more after administration.
Age-group administration rules	For use in dogs ge 1 kg bodyweight and ge 2 months of age.
Special procedural conditions	Tablets can be divided into two equal halves to ensure accurate bodyweight-based dosing. Dogs kept together should be treated simultaneously.

---

Resulting Procedural Structure

The protocol establishes the use of Dolpac 10 as a single administration delivered by the oral route under specific fasting conditions. This involves a precise, weight-dependent dosing calculation, facilitated by the tablet's divisibility to ensure the correct dose rate per kilogram is achieved.

Research Evidence / Overview of Studies for Dolpac 10

---

Evidence for Use in Mixed Gastrointestinal Parasite Infestations

The foundation of the evidence for this medicine relies on controlled, international, multicentre, blind, and randomised trials (RCTs), along with large multicentre field studies. These are the types of research applied in studies evaluating the effect of the drug combination against key adult-stage nematode (roundworm, hookworm, whipworm) and cestode (tapeworm) species. Research examined how findings compared between the medicine and other available treatments or control groups.

Researchers focused on parasitological endpoints to monitor findings related to the medicine's administration. For roundworms, hookworms, and whipworms, studies monitored the reduction in the number of eggs per gram of faeces (EPG) following administration. For tapeworms, the primary outcome measured was the absence of proglottids or eggs in the stool. These findings describe patterns observed in the studies and provided the data for the regulatory assessment related to these conditions.

Long-Term Studies and Follow-Up Duration

Studies monitored the animals over defined time intervals that were generally short-term. The most common follow-up points cited in the primary efficacy research were Day 7, Day 14, and Day 21 following a single dose. While this research describes short-term changes, long-term outcomes are not fully established.

There is limited information for long-term outcomes and the duration over which parasitological non-detection continues beyond the initial three-week post-treatment follow-up period is not well characterized. The evidence is limited to observing responses over these defined time intervals, and research does not provide extended-duration data on the maintenance of parasite-free status.

What Research Still Indicates as Uncertain

Regulatory warnings documented in the research highlight areas of uncertainty and limitation. One key limitation is that study findings note that some parasite species, such as Ancylostoma caninum and Toxocara canis, was not entirely absent in all observed animals. Additionally, the evidence indicates that the long-term status of certain tapeworm species (Dipylidium caninum) was found to be associated with the concurrent control of the intermediate host, such as fleas. Furthermore, the general potential for parasite resistance to anthelmintic classes following repeated or frequent use is a recognized limitation documented in the research landscape.

Key Studies & References Summary of Product Characteristics (SPC) - Dolpac 10 (Veterinary Medicinal Product)

Common questions about Dolpac 10 (FAQ)

---

Q: Is Dolpac 10 the same as Dolpac 5 or Dolpac 20?

A: According to official documentation, the Dolpac product line includes various dosage strengths, such as Dolpac 10 and Dolpac 25, which contain varying concentrations of the active ingredients—Praziquantel, Oxantel, and Pyrantel—and are formulated to match different dog body weights.

Q: What exactly does the '10' in Dolpac 10 mean?

A: The number '10' in the product name is related to the unit of administration. Official guidelines associate this strength with a dosing requirement of one tablet for every 10 kilograms of the dog's body weight.

Q: How quickly does Dolpac 10 usually start working?

A: Research examining the drug’s pharmacological properties indicates that the components, such as Praziquantel and Pyrantel, are readily absorbed after administration. Studies show these components typically reach their highest concentration in the animal’s blood within approximately one to two hours.

Q: How long does one dose of Dolpac 10 stay active in the body?

A: The time the active ingredients remain present in the body can vary. For instance, studies on the Praziquantel component describe a short elimination half-life, which is the time it takes for half the substance to be removed, ranging between 0.8 and 1.5 hours after being given.

Q: Does Dolpac 10 cause drowsiness or fatigue?

A: Official safety information includes occasional reports of adverse reactions involving the nervous system, such as ataxia (a lack of coordination) and muscle tremors. Regulatory documents do not explicitly list drowsiness or fatigue as specific common adverse reactions.

Q: Are there any foods or supplements that should be avoided with Dolpac 10?

A: Official product information describes conditions for administration, indicating that fasting is preferred prior to treatment. Regulatory documents specify certain other medicinal agents that must not be used simultaneously, but they do not list specific dietary supplements to avoid.

Q: Why would a doctor prescribe Dolpac 10 instead of a similar drug?

A: Dolpac 10 is described as a triple-active combination that is designed to provide a wider spectrum of action. Official pharmacological information notes that the inclusion of Oxantel extends its documented coverage to certain nematodes, such as whipworms, that might not be fully susceptible to other components alone.

Q: Is Dolpac 10 a narcotic or addictive substance?

A: Regulatory documents classify Dolpac 10 as a veterinary medicinal product that requires a prescription. It is not described in official documentation as a controlled, scheduled, or addictive substance.

Q: Where can I find the official prescribing information for Dolpac 10?

A: The most detailed official information for the product, such as the Summary of Product Characteristics (SmPC) or package leaflet, is available through government-run drug information databases for veterinary medicines.

Q: Is Dolpac 10 available without a prescription?

A: According to the legal status of supply defined in official documentation, Dolpac 10 is classified as a veterinary medicinal product subject to veterinary prescription.

Q: Why do some people report dizziness when starting Dolpac 10?

A: Regulatory documents for this veterinary product report occasional adverse reactions involving the nervous system, such as ataxia (lack of coordination). Ataxia is the specific effect described in official texts that may be observed by owners and potentially perceived as dizziness.

Q: What should I do if I think I'm having an allergic reaction to Dolpac 10?

A: The product is contraindicated, meaning its use is precluded, in animals with known hypersensitivity (severe allergic reaction) to any of its components. Additionally, regulatory texts advise handlers with a known hypersensitivity to the components to avoid all contact with the product.

Q: Can Dolpac 10 be split or crushed if swallowing is difficult?

A: Regulatory documents state that the tablets can be divided into two equal halves. This feature is intended to ensure accurate weight-based dosing. However, crushing of the tablet is not addressed or sanctioned in the official product information.

Q: What is the chance of experiencing a serious side effect from Dolpac 10?

A: Official documents list specific adverse reactions, such as vomiting, diarrhoea, ataxia, and muscle tremors, providing general frequency terms like 'may occur' or 'occasional reports.' They do not provide a numerical percentage to quantify the chance of experiencing a serious effect.

Q: Does Dolpac 10 affect fertility?

A: Official safety constraints note that the safety of the product has not been established for use in pregnant or lactating animals. Additionally, the regulatory information indicates that use has not been specifically tested in breeding dogs.

Q: What should I avoid doing while the medication is active?

A: Regulatory documents indicate that fasting is preferred prior to treatment, and certain medicinal agents are specified for prohibition from simultaneous use. Additionally, official texts include directions for handlers to wash their hands after use to prevent personal contact.

Q: Is it possible to develop a tolerance to the effects of Dolpac 10?

A: Regulatory warnings highlight the possibility that the development of parasite resistance to anthelmintic classes may occur. This is a recognized limitation that follows frequent and repeated use of any product from that specific class.

Q: Can I take other prescription medications while on Dolpac 10?

A: Official documentation explicitly lists specific agents (such as Levamisole and Piperazine) and the entire class of choline esterase inhibitors as prohibited from simultaneous use.

Q: What are the most common reasons why patients stop taking Dolpac 10?

A: Official documents list vomiting and diarrhoea as possible adverse effects that may be observed following treatment. Additionally, a known hypersensitivity to any component is listed as a major contraindication, which is a key reason for not using or stopping the product.

How to Store and Dispose of Dolpac 10?

The storage and disposal of Dolpac 10 tablets must comply strictly with the conditions defined in the official regulatory documentation.

Storage Requirements

The product does not require any special storage conditions related to temperature or environment. It is mandated that the medicine be kept out of the reach and sight of children. Dolpac 10 must not be used after the expiry date (EXP) stated on the carton.

Handling and Stability

Due to stability constraints, any unused half tablet must be discarded immediately after scoring.

Disposal Instructions

For disposal of unused or expired product, users must consult with their veterinary surgeon for guidance on required procedures. The disposal measures are intended to help protect the environment and must be carried out in accordance with current local regulations on waste materials.